A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies

NCT00406809 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

81

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Lymphoid Leukemia
Lymphoid Malignancies
Non-Hodgkin's Lymphoma
Follicular Lymphoma
Mantle Cell Lymphoma
Peripheral T-cell Lymphoma

Interventions

DRUG: ABT-263

Sponsor

AbbVie (prior sponsor, Abbott)